STRO - Sutro Biopharma - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-149.2M

Cash

391.6M

Avg Qtr Burn

-12.55M

Short % of Float

4.05%

Insider Ownership

1.00%

Institutional Own.

94.14%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Luvelta (STRO-002) (FolRα-Targeting ADC) Details Ovarian cancer, Cancer, Endometrial cancer	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
STRO-001 (BN301) (CD74-Targeting ADC) Details Cancer, B-cell lymphoma, Follicular lymphoma, Lymphoma, Mantle cell lymphoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
M1231 (MUC1-EGFR Bispecific ADC) Details Solid tumor/s, Esophageal cancer, Non-small cell lung carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.